Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Van Antwerpen

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
European Journal of Pharmacology|August 4, 2004
In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide familiesPierre Van Antwerpen, Jean Nève
Expert Opinion on Therapeutic Patents|June 9, 2020
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)Jalal Soubhye, Pierre Van Antwerpen, François Dufrasne
Current Medicinal Chemistry|January 19, 2018
Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory AgentsJalal Soubhye, Pierre van Antwerpen, Francois Dufrasne
Antioxidants & Redox Signaling|February 11, 2021
Selenocompounds and Sepsis: Redox Bypass Hypothesis for Early Diagnosis and Treatment: Part A-Early Acute Phase of Sepsis: An Extraordinary Redox Situation (Leukocyte/Endothelium Interaction Leading to Endothelial Damage)Xavier Forceville, Pierre Van Antwerpen, Jean-Charles Preiser
Journal of Food Biochemistry|February 19, 2021
Anti-inflammatory, antioxidant effects, and bioaccessibility of Tigzirt propolisMokhtaria Yasmina Boufadi, Jalal Soubhye, Pierre Van Antwerpen
Antioxidants & Redox Signaling|March 15, 2022
Selenocompounds and Sepsis-Redox Bypass Hypothesis: Part B-Selenocompounds in the Management of Early SepsisXavier Forceville, Pierre Van Antwerpen, Djillali Annane, et al.
Future Medicinal Chemistry|August 1, 2015
Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosisJalal Soubhye, Ibaa Chikh Alard, Pierre van Antwerpen, et al.
Archives of Biochemistry and Biophysics|April 4, 2018
The other myeloperoxidase: Emerging functionsLuc Vanhamme, Karim Zouaoui Boudjeltia, Pierre Van Antwerpen, et al.
Frontiers in Microbiology|April 10, 2023
Two new siderophores produced by <i>Pseudomonas</i> sp. NCIMB 10586: The anti-oomycete non-ribosomal peptide synthetase-dependent mupirochelin and the NRPS-independent triabactinCamille Grosse, Nathalie Brandt, Pierre Van Antwerpen, et al.
Analytica Chimica Acta|April 30, 2016
Glycan characterization of biopharmaceuticals: Updates and perspectivesAna Planinc, Jonathan Bones, Bieke Dejaegher, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
European Journal of Pharmacology|August 4, 2004
In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide familiesPierre Van Antwerpen, Jean Nève
Expert Opinion on Therapeutic Patents|June 9, 2020
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)Jalal Soubhye, Pierre Van Antwerpen, François Dufrasne
Current Medicinal Chemistry|January 19, 2018
Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory AgentsJalal Soubhye, Pierre van Antwerpen, Francois Dufrasne
Antioxidants & Redox Signaling|February 11, 2021
Selenocompounds and Sepsis: Redox Bypass Hypothesis for Early Diagnosis and Treatment: Part A-Early Acute Phase of Sepsis: An Extraordinary Redox Situation (Leukocyte/Endothelium Interaction Leading to Endothelial Damage)Xavier Forceville, Pierre Van Antwerpen, Jean-Charles Preiser
Journal of Food Biochemistry|February 19, 2021
Anti-inflammatory, antioxidant effects, and bioaccessibility of Tigzirt propolisMokhtaria Yasmina Boufadi, Jalal Soubhye, Pierre Van Antwerpen
Antioxidants & Redox Signaling|March 15, 2022
Selenocompounds and Sepsis-Redox Bypass Hypothesis: Part B-Selenocompounds in the Management of Early SepsisXavier Forceville, Pierre Van Antwerpen, Djillali Annane, et al.
Future Medicinal Chemistry|August 1, 2015
Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosisJalal Soubhye, Ibaa Chikh Alard, Pierre van Antwerpen, et al.
Archives of Biochemistry and Biophysics|April 4, 2018
The other myeloperoxidase: Emerging functionsLuc Vanhamme, Karim Zouaoui Boudjeltia, Pierre Van Antwerpen, et al.
Frontiers in Microbiology|April 10, 2023
Two new siderophores produced by <i>Pseudomonas</i> sp. NCIMB 10586: The anti-oomycete non-ribosomal peptide synthetase-dependent mupirochelin and the NRPS-independent triabactinCamille Grosse, Nathalie Brandt, Pierre Van Antwerpen, et al.
Analytica Chimica Acta|April 30, 2016
Glycan characterization of biopharmaceuticals: Updates and perspectivesAna Planinc, Jonathan Bones, Bieke Dejaegher, et al.
Pageof 13